Novel drug delivery system based on docetaxel-loaded nanocapsules as a therapeutic strategy against breast cancer cells

International Journal of Molecular Sciences

Volumn 13, Issue 4, 2012, Pages 4906-4919

  Sánchez Moreno, Paola ^a   Boulaiz, Houria ^a   Ortega Vinuesa, Juan Luis ^a   Peula García, José Manuel ^a,b   Aránega, Antonia ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Breast cancer; Docetaxel; Drug delivery; Lipid nanoparticles

Indexed keywords

DOCETAXEL; FLUORESCEIN ISOTHIOCYANATE; LIPID NANOCAPSULE; LIPOCORTIN 5; NANOCAPSULE; PROPIDIUM IODIDE; SULFORHODAMINE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIPID; TAXOID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CARCINOMA CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG UPTAKE; ENCAPSULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; SOLVENT EXTRACTION; SYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; FEMALE; M PHASE CELL CYCLE CHECKPOINT; MCF 7 CELL LINE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPIDS; M PHASE CELL CYCLE CHECKPOINTS; MCF-7 CELLS; NANOCAPSULES; TAXOIDS;

EID: 84860144950     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13044906     Document Type: Article

References (44)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
2. Jemal, A.; Bray, F.; Center M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
3. Verma, S.; Lavasani, S.; Mackey, J.; Pritchard, K.; Clemons, M.; Dent, S.; Latreille, J.; Lemieux, J.; Provencher, L.; Verma, Sh., et al. Optimizing the management of HER2-positive early breast cancer: The clinical reality. Curr. Oncol. 2010, 17, 20-33.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005, 365, 1687-1717.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998, 352, 930-942.
6. Qin, Y.Y.; Li, H.; Guo, X.J.; Ye, X.F.; Wei, X.; Zhou, Y.H.; Zhang, X.J.; Wang, C.; Qian, W.; Lu, J., et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: A meta-analysis of 19 randomized trials with 30698 patients. PLoS One 2011, 6, doi:10.1371/journal.pone.0026946.
7. Peer, D.; Karp, J.M.; Hong, S.; Farokhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2, 751-760.
8. Olson, R.D.; Mushlin, P.S. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J. 1990, 4, 3076-3086.
9. Ma, Y.; Zheng, Y.; Zeng, X.; Jiang, L.; Chen, H.; Liu, R.; Huang, L.; Mei, L. Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment. Int. J. Nanomed. 2011, 6, 2679-2688.
10. Blanco, E.; Hsiao, A.; Mann, A.P.; Landry, M.G.; Meric-Bernstam, F.; Ferrari, M. Nanomedicine in cancer therapy: Innovative trends and prospects. Cancer Sci. 2011, 102, 1247-1252.
11. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2, 347-360.
12. Strebhardt, K.; Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. 2008, 8, 473-480.
13. Boulaiz, H.; Alvarez, P.J.; Ramirez, A.; Marchal, J.A.; Prados, J.; Rodríguez-Serrano, F.; Perán, M.; Melguizo, C.; Aranega, A. Nanomedicine: Application areas and development prospects. Int. J. Mol. Sci. 2011, 12, 3303-3321.
14. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzym. Regul. 2001, 41, 189-207.
15. Couvreur, P.; Barratt, G.; Fattal, E.; Legrand, P.; Vauthier, C. Nanocapsule technology: A review. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19, 99-134.
16. Sánchez-Moreno, P.; Ortega-Vinuesa, J.L.; Martín-Rodríguez, A.; Boulaiz, H.; Marchal, J.A.; Peula-García, J.M. Characterization of different functionalized lipidic nanocapsules as potential drug carriers. Int. J. Mol. Sci. 2012, 13, 2405-2424.
17. Immordino, M.L.; Brusa, P.; Arpicco, S.; Stella, B.; Dosio, F.; Cattel, L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J. Control. Release 2003, 91, 417-429.
18. Earhart, R.H. Docetaxel (taxotere): Preclinical and general clinical information. Semin. Oncol. 1999, 26, 8-13.
19. Verweij, J. Docetaxel (taxotere™): A new anti-cancer drug with promising potential? Br. J. Cancer 1994, 70, 183-184.
20. Piccart, M.J.; di Leo, A. Future perspectives of docetaxel (taxotere) in front-line therapy. Semin. Oncol. 1997, 24, S1027-S1033.
21. Lee, S.W.; Yun, M.H.; Jeong, S.W.; In, C.H.; Kim, J.Y.; Seo, M.H.; Pai, C.M.; Kim, S.O. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. J. Control. Release 2011, 155, 262-271.
22. Weiszhár, Z.; Czúcz, J.; Révész, C.; Rosivall, L.; Szebeni, J.; Rozsnyay, Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur. J. Pharm. Sci. 2011, 45, 492-498.
23. Zhao, M.; Su, M.; Lin, X.; Luo, Y.; He, H.; Cai, C.; Tang, X. Evaluation of docetaxel-loaded intravenous lipid emulsion: Pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity. Pharm. Res. 2010, 27, 1687-1702.
24. Gao, K.; Sun, J.; Liu, K.; Liu, X.; He, Z. Preparation and characterization of a submicron lipid emulsion of docetaxel: Submicron lipid emulsion of docetaxel. Drug Dev. Ind. Pharm. 2008, 34, 1227-1237.
25. Sahu, A.; Kasoju, N.; Goswami, P.; Bora, U. Encapsulation of curcumin in Pluronic block copolymer micelles for drug delivery applications. J. Biomater. Appl. 2011, 25, 619-639.
26. Ray, S.D. Potential aspects of chitosan as pharmaceutical excipient. Acta Pol. Pharm. 2011, 68, 619-622.
27. Wasan, K.M. The biological functions of lipid excipients and the implications for pharmaceutical products development. J. Pharm. Sci. 2009, 98, 379-382.
28. Anbharasi, V.; Cao, N.; Feng, S.S. Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J. Biomed. Mater. Res. A 2010, 94, 730-743.
29. Florence, A.T.; Hussain, N. Transcytosis of nanoparticle and dendrimer delivery systems: Evolving vistas. Adv. Drug Deliv. Rev. 2001, 50, 69-89.
30. Sandri, G.; Bonferoni, M.C.; Rossi, S.; Ferrari, F.; Gibin, S.; Zambito, Y.; di Colo, G.; Caramella, C. Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur. J. Pharm. Biopharm. 2007, 65, 68-77.
31. Lozano, M.V.; Torrecilla, D.; Torres, D.; Vidal, A.; Dominguez, F.; Alonso, M.J. Highly efficient system to deliver taxanes into tumor cells: Docetaxel-loaded chitosan oligomer colloidal carriers. Biomacromolecules 2008, 9, 2186-2193.
32. Hafner, A.; Lovric, J.; Voinovich, D.; Filipovic-Grcic, J. Melatonin-loaded lecithin/chitosan nanoparticles: Physicochemical characterization and permeability through Caco-2 cell monolayers. Int. J. Pharm. 2009, 381, 205-213.
33. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J.P. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials 2006, 27, 4356-4373.
34. Beduneau, A.; Saulnier, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28, 4947-4967.
35. Youm, I.; Yang, X.Y.; Murowchick, J.B.; Youan, B.B. Encapsulation of docetaxel in oily core polyester nanocapsule intended for breast cancer therapy. Nanoscale Res. Lett. 2011, 6, doi:10.1186/1556-276X-6-630.
36. Li, P.Y.; Lai, P.S.; Hung, W.C.; Syu, W.J. Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells. Biomacromolecules 2010, 11, 2576-2582.
37. Montero, A.; Fossella, F.; Hortobagyi, G.; Valero, V. Docetaxel for treatment of solid tumours: A systematic review of clinical data. Lancet Oncol. 2005, 6, 229-239.
38. Chadderton, A.; Villeneuve, D.J.; Gluck, S.; Kirwan-Rhude, A.F.; Gannon, B.R.; Blais, D.E.; Parissenti, A.M. Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res. Treat. 2000, 59, 231-244.
39. Marchal, J.A.; Núñez, M.C.; Suárez, I.; Díaz-Gavilán, M.; Gómez-Vidal, J.A.; Boulaiz, H.; Rodríguez-Serrano, F.; Gallo, M.A.; Espinosa, A.; Aránega, A., et al. A synthetic uracil derivative with antitumor activity through decreasing cyclin D1 and Cdk1, and increasing p21 and p27 in MCF-7 cells. Breast Cancer Res. Treat. 2007, 105, 237-246.
40. Hernández-Vargas, H.; Palacios, J.; Moreno-Bueno, G. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: Uncoupling of aberrant mitosis and apoptosis. Oncogene 2007, 26, 2902-2913.
41. Liu, D.; Liu, Z.; Wang, L.; Zhang, C.; Zhang, N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf. B Biointerfaces 2011, 85, 262-269.
42. Sharma, R.I.; Welch, A.E.; Schweiger, L.; Craib, S.; Smith, T.A. 18F]Fluoro-2-deoxy-D-glucose incorporation by MCF-7 breast tumour cells in vitro is modulated by treatment with tamoxifen, doxorubicin, and docetaxel: Relationship to chemotherapy-induced changes in ATP content, hexokinase activity, and glucose transport. Int. J. Mol. Imaging 2011, 2011, doi:10.1155/2011/874585.
43. Ghawanmeh, T.; Thunberg, U.; Castro, J.; Murray, F.; Laytragoon-Lewin, N. MiR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment. Oncology 2012, 10, 330-335.
44. Villalobos, M.; Olea, N.; Brotons, J.A.; Olea-Serrano, M.F.; Ruiz de Almodovar, J.M.; Pedraza, V. The E-Screen assay: A comparison of different MCF-7 cell stocks. Environ. Health Perspect. 1995, 9, 844-849.